Introducing Our New Board Members

Barry S. Coller, M.D.
Physician-in-Chief and Vice President for Medical Affairs, Rockefeller University, New York, NY

Barry S. Coller, M.D. is the David Rockefeller Professor of Medicine; Head, Allen and Frances Adler Laboratory of Blood and Vascular Biology; Physician-in-Chief of The Rockefeller University Hospital; and Vice President for Medical Affairs at The Rockefeller University. He is also founding Director of the Rockefeller University Center for Clinical and Translational Science and Principal Investigator of the University’s Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences. From 1993 to 2001, Dr. Coller was the Murray M. Rosenberg Professor of Medicine and Chairman of the Samuel Bronfman Department of Medicine at Mount Sinai School of Medicine in New York City. Before that he was Professor of Medicine and Chief of the Division of Hematology at Stony Brook University.

Dr. Coller’s research interests focus on platelet physiology.  He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoProÔ; Centocor). It was approved in 1994 to prevent ischemic complications of coronary interventions such as angioplasty and stent insertion. More than 5.0 million patients have been treated with abciximab. He also helped develop the VerifyNow assays (Accumetrics) to monitor antiplatelet therapy with aspirin, clopidogrel (Plavix™), and other antiplatelet drugs. Dr. Coller is the recipient or a co-recipient of twenty-two U.S. patents.

Dr. Coller has served as President of the American Society of Hematology and as founding President of the Society for Clinical and Translational Science. Dr. Coller is a member of Phi Beta Kappa, Alpha Omega Alpha, the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences. He serves on the NASEM Forum on Drug Discovery, Development, and Translation, as well as the Board on Health Sciences Policy.

David Goldsteen, M.D.
Chairman and CEO, VigiLanz Corporation, Minneapolis, MN

David Goldsteen is a successful physician, healthcare executive and serial medical technology entrepreneur. Dr. Goldsteen was the founder or financial backer of among other companies, Vascular Science, SurvivaLink and MediaDVX.  He is the co-founder and currently serves as Chairman and CEO of VigiLanz, a real time clinical intelligence and analytics company for health care provider organizations. Dr. Goldsteen is the co-recipient of 29 patents in the areas of cardiac devices and medical informatics. He previously served as a Medical Affairs vice-president for Health One, a predecessor of Allina Health, and served on the Advisory Board of the Biomedical Ethics Program at the University of Minnesota. His clinical specialties include Emergency Medicine and Internal Medicine.

Dr. Goldsteen received his B.E.S., M.D., and M.B.A degrees from the University of Minnesota.  He splits time between Minneapolis, Minnesota and Naples, Florida.

Sylvia Morris, M.D., M.P.H., BSPH ’97
Hospitalist, Kaiser Permanente, Media Speaker, Decatur, GA

Sylvia E. Morris, MD, MPH is an Internist at Kaiser Permanente.

Dr. Morris’s goal is to utilize media to improve our nation’s public health by combining her training in Internal Medicine, Holistic Medicine and Public Health.  To this end, she has made guest appearances on the Weather Channel’s Weekend View, CNN International, and a former contributor for the US News & World Report Medical School Admissions’ blog.

Dr. Morris, a Kaiser Permanente Brand Ambassador, serves on Western Governors University College of Health Professions Nursing Advisory Council.

Most recently, Dr. Morris was a Senior Medical Director on the Revenue Cycle Solutions team at The Advisory Board Company. Formerly, a Medical Director for CVS Minute Clinic and an Assistant Professor of Medicine at the Emory University School of Medicine working as a Hospitalist and developer of health promotions lectures and social media content.

Dr. Morris earned a bachelor’s degree in Molecular and Cell Biology from the University of California at Berkeley. She gained a master’s degree in Public Health at Johns Hopkins University Bloomberg School of Public Health, with a certificate in Health Policy and Management.  Her medical degree is from Georgetown University School of Medicine.  She completed residency in Internal Medicine at the University of Washington Medical Center, Seattle.

Amy Engel Scharf ’90
Memorial Sloan Kettering Cancer Center Ethics Consultation Service and Ethics Committee, New York, NY

Amy Engel Scharf is a project manager for Memorial Sloan Kettering Cancer Center Ethics Consultation Service and a member of their Ethics Committee. She is also Chair of the Board of Trustees for Children’s Aid, a social service non-profit that provides comprehensive health, education, and social supports to New York City’s most vulnerable children.

Amy graduated from Johns Hopkins in 1990 with a BA in International Relations and holds master’s degrees from Yale University in Russian & East European Studies (1992) and Columbia University in Bioethics (2016).

Maxwell Thanhouser
Managing Partner, Fenorton, LLC Owing Mills, MD

Maxwell Thanhouser is the managing partner of Fenorton, LLC, a single-family office managing the assets of four generations based in Owings Mills, Maryland.  Fenorton focuses on traditional investment activities in addition to private real estate, private equity, and private debt markets.

Mr. Thanhouser is also the managing member of Conflux Financial, LLC, an operating company for real estate acquisitions and management, direct ownership and management of properties, as well as Limited Partner investments throughout the project cycle and asset classes.

Previously, he was the managing partner of Saffron Trading Group, a boutique proprietary trading firm specializing in the grain and treasury markets. Prior to that, Mr. Thanhouser worked as an aerospace defense consultant focused on strategic work and mergers and acquisitions due diligence for Renaissance Strategic Advisors, based in Arlington, Virginia.

He is a director-at-large at the Associated Jewish Charities and a board member at Sinai Hospital of Baltimore, MD.

Mr. Thanhouser is a member of the third cohort of the Leadership Fellows (2019-21). He was nominated by central Development and Alumni Relations. He holds a bachelor’s degree from the Questrom School of Business at Boston University and a master’s degree in engineering and technology innovation management from Carnegie Mellon University.